中国泰凌医药集团始创于1995年，是一家集研发、生产、销售为一体的国际化制药集团公司，在香港联合交易所主板上市（股份代号：.HK）。集团总部位于香港，在上海设有投资及营销管理中心，在北京设有研发及医学事务中心，在苏州、泰州、长沙及瑞士建有生产基地，拥有10余家全资或控股的生产及销售公司。 集团的核心产品覆盖了肿瘤及血液系统疾病、骨代谢疾病、消化系统疾病、中枢神经系统疾病、呼吸系统疾病等多个治疗领域，现由CSO招商团队全面转型为自营销售推广团队。 China NT Pharma Group Company Limited, founded in1995, a comprehensive listed pharmaceutical factory engaged in investment, R&D, production, marketing and promotion of medicines and new medicinal technologies (Stock Code: . HK).Headquartered in Hong Kong, with marketing、research and medical business center based in Shanghai, Beijing and Guangzhou. Our main pharmaceutical manufacturing plants located in Suzhou, Taizhou, Changsha and Switzerland. Currently NT Pharma Group has more than 10 subsidiaries. We focus on development of core products covering tumor and Hematological system, central nervous system, chronic, bone metabolic, generic pharmaceutical and other therapeutic fields. According to our strategy, now we have fully transformed into self-management model. With the mission of “serving healthy life”, we take credibility as the cornerstone, innovation as the driving force, strive for excellence, and focused on human resources with talent，determined to become an excellent medical &health enterprise and contribute to human health.